These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3036389)

  • 1. Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma.
    Reece PA; Bishop JF; Olver IN; Stafford I; Hillcoat BL; Morstyn G
    Cancer Chemother Pharmacol; 1987; 19(4):326-30. PubMed ID: 3036389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of carboplatin after i.v. administration.
    Elferink F; van der Vijgh WJ; Klein I; Vermorken JB; Gall HE; Pinedo HM
    Cancer Treat Rep; 1987 Dec; 71(12):1231-7. PubMed ID: 3319135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.
    Siddik ZH; Newell DR; Boxall FE; Harrap KR
    Biochem Pharmacol; 1987 Jun; 36(12):1925-32. PubMed ID: 3297068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer.
    Reece PA; Morris RG; Bishop JF; Olver IN; Raghavan D
    Cancer Res; 1987 Jun; 47(11):2996-9. PubMed ID: 2952262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The disposition of carboplatin in ovarian cancer patients.
    Gaver RC; Colombo N; Green MD; George AM; Deeb G; Morris AD; Canetta RM; Speyer JL; Farmen RH; Muggia FM
    Cancer Chemother Pharmacol; 1988; 22(3):263-70. PubMed ID: 3044634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of unchanged cisplatin in patients with ovarian cancer.
    Reece PA; Stafford I; Davy M; Freeman S
    Clin Pharmacol Ther; 1987 Sep; 42(3):320-5. PubMed ID: 3621787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of carboplatin in children.
    Riccardi R; Riccardi A; Lasorella A; Di Rocco C; Carelli G; Tornesello A; Servidei T; Iavarone A; Mastrangelo R
    Cancer Chemother Pharmacol; 1994; 33(6):477-83. PubMed ID: 8137457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The disposition of carboplatin in the beagle dog.
    Gaver RC; George AM; Duncan GF; Morris AD; Deeb G; Faulkner HC; Farmen RH
    Cancer Chemother Pharmacol; 1988; 21(3):197-202. PubMed ID: 3282707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.
    Mulder PO; de Vries EG; Uges DR; Scaf AH; Sleijfer DT; Mulder NH
    Br J Cancer; 1990 Mar; 61(3):460-4. PubMed ID: 2183874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
    Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
    Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of carboplatin.
    Oguri S; Sakakibara T; Mase H; Shimizu T; Ishikawa K; Kimura K; Smyth RD
    J Clin Pharmacol; 1988 Mar; 28(3):208-15. PubMed ID: 3283185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of hematologic toxicity of carboplatin by creatinine clearance rate.
    Taguchi J; Saijo N; Miura K; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sakurai M; Minato K; Fujiwara Y
    Jpn J Cancer Res; 1987 Sep; 78(9):977-82. PubMed ID: 3117753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.
    O'Dwyer PJ; Hudes GR; Walczak J; Schilder R; LaCreta F; Rogers B; Cohen I; Kowal C; Whitfield L; Boyd RA
    Cancer Res; 1992 Dec; 52(24):6746-53. PubMed ID: 1458462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.
    Honoré PH; Joensen SJ; Olsen M; Hansen SH; Mellemgaard A
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):349-57. PubMed ID: 24934863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment.
    Mancinelli A; D'Iddio S; Bisonni R; Graziano F; Lippe P; Calvani M
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):19-26. PubMed ID: 16988826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
    Egorin MJ; Van Echo DA; Tipping SJ; Olman EA; Whitacre MY; Thompson BW; Aisner J
    Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of vinorelbine.
    Levêque D; Jehl F
    Clin Pharmacokinet; 1996 Sep; 31(3):184-97. PubMed ID: 8877249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography.
    Jehl F; Quoix E; Leveque D; Pauli G; Breillout F; Krikorian A; Monteil H
    Cancer Res; 1991 Apr; 51(8):2073-6. PubMed ID: 1849042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A phase I study of carboplatin].
    Ogawa M; Imajo K; Horikoshi N; Inoue K; Mukaiyama T; Yamazaki H; Ueno K; Nakamura T; Aiba K; Kuraishi Y
    Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1292-6. PubMed ID: 3034170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.